| EORTC Quality of Life Measurement in Males With Breast Cancer (NCT07455110) | Helios University Hospital Wuppertal | 2019-11-01 |
| Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (NCT03018080) | Wake Forest University Health Sciences | 2017-06-12 |
| Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens (NCT02480933) | Centro Hospitalar Lisboa Ocidental | 2016-09-01 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (NCT02580448) | Innocrin Pharmaceutical | 2015-08-01 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer (NCT01938833) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-04-01 |
| Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience (NCT03240510) | Salah Azaïz Cancer Institute | 2014-01-01 |
| Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer (NCT01869764) | Wake Forest University Health Sciences | 2013-11-01 |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT02046421) | University of Chicago | 2013-11-01 |
| Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer (NCT01868503) | Stanford University | 2013-07-01 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (NCT01783756) | Jonsson Comprehensive Cancer Center | 2013-06-26 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (NCT01806675) | Sanjiv Sam Gambhir | 2013-03-04 |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases (NCT01939483) | University of California, Irvine | 2012-12-01 |
| Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer (NCT01729884) | University of Washington | 2012-12-01 |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (NCT01720602) | University of Washington | 2012-11-01 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (NCT01638247) | GBG Forschungs GmbH | 2012-08-01 |
| Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer (NCT01632332) | Mayo Clinic | 2012-07-09 |
| Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer (NCT01219907) | University of Washington | 2012-06-01 |
| FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer (NCT01931709) | University of Washington | 2011-11-01 |
| Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (NCT01372579) | Northwestern University | 2011-08-01 |
| Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (NCT01394211) | University of Arizona | 2011-07-13 |
| Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (NCT01355393) | University of Washington | 2011-07-01 |
| Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021). (NCT01703520) | Organon and Co | 2011-05-01 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01288261) | University of Arizona | 2011-01-01 |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy (NCT01153672) | University of Washington | 2010-11-01 |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer (NCT01245205) | National Cancer Institute (NCI) | 2010-11-01 |
| Endoscopic Breast Surgery in Treating Patients With Breast Cancer (NCT01222377) | University of Southern California | 2010-09-01 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer (NCT01104259) | University of Washington | 2010-07-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer (NCT01151449) | National Cancer Institute (NCI) | 2010-06-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer (NCT01084057) | City of Hope Medical Center | 2010-05-17 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (NCT01100489) | Case Comprehensive Cancer Center | 2010-02-01 |
| Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer (NCT01042535) | H. Lee Moffitt Cancer Center and Research Institute | 2009-12-28 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer (NCT00821964) | University of Washington | 2008-12-01 |
| Vaccine Therapy in Treating Patients With Stage IV Breast Cancer (NCT00791037) | University of Washington | 2008-10-01 |
| Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery (NCT00559507) | National Cancer Institute (NCI) | 2007-10-01 |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT00513695) | University of Washington | 2007-06-01 |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer (NCT00470301) | National Cancer Institute (NCI) | 2007-04-01 |
| Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer (NCT00368875) | National Cancer Institute (NCI) | 2006-07-01 |
| AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery (NCT00348699) | National Cancer Institute (NCI) | 2006-07-01 |
| Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer (NCT00331552) | University of Washington | 2006-02-01 |
| Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer (NCT00343863) | University of Washington | 2006-01-01 |
| Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer (NCT00119262) | National Cancer Institute (NCI) | 2005-10-01 |
| ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment (NCT00425672) | University of Washington | 2005-09-01 |
| A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) (NCT00244881) | National Cancer Institute (NCI) | 2005-09-01 |
| Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer (NCT00077376) | National Cancer Institute (NCI) | 2005-03-01 |
| FR901228 in Treating Patients With Metastatic Breast Cancer (NCT00098397) | National Cancer Institute (NCI) | 2005-02-01 |
| 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer (NCT00095888) | National Cancer Institute (NCI) | 2004-10-01 |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases (NCT00098605) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib in Treating Patients With Metastatic Breast Cancer (NCT00096434) | National Cancer Institute (NCI) | 2004-09-01 |
| Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (NCT00343109) | University of Washington | 2004-03-01 |
| GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer (NCT00068588) | National Cancer Institute (NCI) | 2003-10-01 |
| Vaccine Therapy in Treating Patients With Metastatic Breast Cancer (NCT00071942) | National Cancer Institute (NCI) | 2003-10-01 |
| Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer (NCT00063934) | National Cancer Institute (NCI) | 2003-05-01 |
| Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer (NCT00045188) | National Cancer Institute (NCI) | 2002-08-01 |
| Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer (NCT00039455) | National Cancer Institute (NCI) | 2002-04-01 |
| Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer (NCT00024154) | National Cancer Institute (NCI) | 2002-02-01 |
| Decitabine in Treating Patients With Advanced Solid Tumors (NCT00030615) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors (NCT00028535) | National Cancer Institute (NCI) | 2001-11-01 |
| Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer (NCT00017394) | National Cancer Institute (NCI) | 2001-03-01 |
| Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer (NCT00006228) | National Cancer Institute (NCI) | 2000-07-01 |
| Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer (NCT00005817) | National Cancer Institute (NCI) | 2000-03-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer (NCT00003199) | Fred Hutchinson Cancer Center | 1997-11-01 |